April 25, 2017
At the Company’s AGM held today the Chairman, Christopher Pearce, made the following statement:
“As stated in our recent results, we expect 2017 to be a transformational year for Proteome Sciences. The combination of strong revenue growth during 2016 and operational initiatives to simplify our strategy, consolidate our resources and broaden our commercial capability, have put the Company in a good position to take advantage of the increasing opportunities afforded by quantitative proteomics. Trading remains in line with management expectations.”
All resolutions at the AGM were duly passed.